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measurement of monocyte procoagulant activity (MPA) after challenge with cartilage-derived antigens in 
OA patients might provide such a marker [4]. 
Therapies currently available for the treatment of OA, for the most part, only modify the symptoms of the 
disease rather than the underlying cause. From laboratory studies [5] and our previous clinical investigations 
[6], we considered that pentosan polysulphate (PPS) offered potential as an agent with disease modifying 
activities in OA. The objective of the present investigation was to evaluate this hypothesis. 
Methods  and Resu l ts  
In this study the effects of 4 weekly intramuscular injections of PPS (3 mg/kg) were determined on OA patients 
(n= 11) symptoms, peripheral blood monocyte procoagulant activity (MPA) [7] and blood white cell 
populations over an initial 24 h period and then 8 weeks thereafter. Clinical assessment continued for weeks 
12, 16, 20 and 24 from initiation of the study. In all patients MPA was reduced relative to baseline pre-drug 
values for up to 24 h post-PPS treatment. In those patients with a moderate, but not mild, grade of OA this 
reduction in MPA was sustained for up to 4 weeks fol lowingthe last (4th) i.m. injection of PPS. The reduction 
in patient's MPA correlated for the moderate OA group, with a decline in many of their clinical symptoms 
including: global pain (r = 0.958), effectiveness of treatment (r = 0.915), pain on walking (r = 0.800) and time 
to climb 15 steps (r = 0.768). The precentage of leucocytes increased in blood of all OA patients receiving PPS, 
maximum levels being achieved after 8 h. The major contribution to this rise in leucocytes was from 
lymphocytes since monocytes and neutrophils actually decreased after PPS treatment. Significantly, 4weeks 
after the last PPS injection the lymphocyte populations were still elevated (p < 0.04) and neutrophils 
depressed (p < 0.04) in the blood 8 of the 11 patients tudied. Platelet levels were also elevated in PPS-treated 
patients relative to their baseline values (p < 0.005). 
Conc lus ion 
The present findings leads us to conclude that monocyte procoagulant activity could provide a useful means 
of monitoring disease progression and patients response to disease modifying drug treatments in OA. This 
study also demonstrated that PPS altered the distribution of leucocytes present in blood of OA patients. Most 
notable was the elevation of the percentage of lymphocytes present and the depression of neutrophil evels 
for up to 4 weeks after the last injection of the drug. Although numbers were small, in those OA patients 
whose lymphocytes and neutrophils levels returned to their baseline values, symptoms re-appeared. From 
these investigations, we conclude that PPS is a drug with an unusual mechanism of action. Apart from its 
known pleotropic actions on connective tissues and epithelium, it now appears that it is also 
immunoregulatory both in terms of leucocyte recruitment and in the expression by these cells of activities 
which are implicated in the pathogenesis of OA. 
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The aim of this paper is to present some of the questions that need to be addressed before interpreting current 
data and conducting future trials and evaluation of intra-articular therapies for asteoarthritis (OA), Patient 
selection, disease subsets, outcome measures, trial setting, symptoms control, drop-outs and placebo response 
will be discussed. 
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Patient Select ion 
We need to be aware that patients assessed by a specialist will be different o those referred by a general 
practitioner and even more so to the highly motivated volunteer OA sufferer who was recruited for the trial 
after reading a newspaper advertisement. 
Disease Subsets 
It is now well recognised that OA of different joints has varying disease onset and progression, combining 
patients in global OA trials may dilute important subset effects. However, the move in recent intra-articular 
therapy trials to find the homogenous nilateral medial tibio-femoral OA in select age, sex and racial groups 
leads to many potential recipients being excluded and makes trial recruitment at a single site impractical. 
Can we use patients with bilateral disease as their own controls? Can we expect patients with bilateral 
disease to accurately assess outcomes? Can we mount large multi-centre trails that include suficient numbers 
in multiple disease subsets? 
Outcome Measures 
Are the current measures that have been well validated for the advanced OA patient undergoing joint 
replacement surgery suitable for the young active patient with early OA whose main aim is to get back to 
running or competition tennis? 
Trial Sett ing and Conduct 
How much influence does the special research clinic and the attentive metrologist have on the patient 
responses? Could or should we mimic "usual patient care"? 
Symptom control 
To evaluate disease modification patients will need to be observed over periods of at least two years. Are 
we expecting too much of the new therapies that they should control symptoms in the immediate and 
long-term? Will combination therapy be required? 
Drop-outs 
Analysis should be by intention-to-treat as placebo-controlled long-term studies for OA to date have had a 
significant differential in drop-out rates between active and placebo arms. Should we encourage patients to 
maintain trail protocol and avoid all other therapies or are we just increasing the chance of finding no 
difference? Drop-out rates should be an important outcome measure. 
Placebo Response 
How can we see a treatment effect when the placebo group report up to 60% treatment satifaction and 
improvement in pain and function? 
Osteoarthritis is a common and disabling condition and the implications of a disease modifying therapy are 
substantial. Once the challenges of radiological biochemical and histopathological assessment of disease 
progression have been met then large multi-centre trials with randomisation within subsets of OA must be 
undertaken. 
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Objective 
Pentosan polysulphate (PPS) (Cartrophen) is a new anti-osteoarthritis drug which from laboratory and 
animal studies [1] offers potential for disease modification in osteoarthritis (OA). The present study was 
